Tidepath

More GLP-1 drugs

Exenatide

Also called Byetta, Bydureon, Bydureon BCise, exendin-4

A GLP-1 drug originally found in the venom of the Gila monster, a lizard145.

Status
Approved by the FDA in 2005 for type 2 diabetes, as Byetta, and now listed by the FDA as discontinued, along with every form of Bydureon and the one generic version of Byetta1678912.
How it's taken
By injection

What it is

Byetta and Bydureon BCise both contain exenatide, a GLP-1 drug12. GLP-1 is a hormone your gut releases when you eat3. Exenatide is a lab-made copy of exendin-4, a peptide originally found in the venom of the Gila monster, a lizard145. Its chain of building blocks (amino acids) partly matches human GLP-1, and it acts on the GLP-1 receptor1. Exenatide raises insulin when blood sugar is high, lowers glucagon (a hormone that raises blood sugar) when glucagon is too high, and slows how fast the stomach empties1. In Byetta, its half-life, the time it takes for half a dose to clear, is about 2.4 hours1. Byetta was injected twice a day, within the hour before the morning and evening meals1. Bydureon BCise holds the same molecule in tiny beads (microspheres) that release it slowly, and was injected once a week2. Byetta was approved to improve blood sugar in adults with type 2 diabetes, and Bydureon BCise in adults and children 10 and older with type 2 diabetes12.

What makes it distinct

The same molecule was made in two forms: a twice-a-day injection (Byetta) and a once-a-week injection that releases it slowly from tiny beads (Bydureon BCise)12.

What the evidence shows

Byetta was studied in adults with type 2 diabetes, on its own and added to other diabetes medicines, including insulin glargine1. In the placebo-controlled trials on its label, HbA1c, a blood test of average blood sugar over the past few months, fell more on Byetta than on placebo, a dummy treatment1. The weekly form was also studied in children aged 10 to 17 with type 2 diabetes2. EXSCEL, a heart-outcomes trial of weekly exenatide, enrolled 14,752 adults with type 2 diabetes, with or without previous heart or blood vessel disease210. Major heart events (a heart attack, a stroke, or death from heart or blood vessel disease) did not differ significantly from placebo10. The trial ruled out a rise in that risk beyond a limit set in advance, but didn't show that weekly exenatide lowered it210. A phase 3 trial in 194 people with Parkinson's disease gave weekly exenatide or placebo for 96 weeks and found no evidence that it slowed the disease11.

Open questions

  • Whether the weekly form causes thyroid tumors in people. In animal studies it caused thyroid C-cell tumors (C-cells are a type of cell in the thyroid), and its label says it isn't known whether that happens in people2.
  • Whether exenatide will be sold in the US again. Byetta, every form of Bydureon and the generic version of Byetta, approved in 2024, are all listed by the FDA as discontinued678912.

Worth knowing

Byetta's label has no boxed warning, but in its animal studies, non-cancerous thyroid growths (C-cell adenomas) were seen in female rats at every dose tested1. Bydureon BCise's label carries a boxed warning about thyroid C-cell tumors in rats2.

Sources

  1. BYETTA (exenatide) injection, prescribing information, AstraZeneca (DailyMed; label effective September 2025)
  2. BYDUREON BCISE (exenatide extended-release) prescribing information, AstraZeneca (FDA, revised May 2025)
  3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
  4. Eng J et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992 (PubMed 1313797)
  5. Alves et al. Anti-obesogenic and hypolipidemic effects of a GLP-1 receptor agonist derived from the saliva of the Gila monster. Toxicon. 2017 (PubMed 28579479)
  6. Drugs@FDA: NDA 021773, BYETTA (exenatide)
  7. Drugs@FDA: NDA 022200, BYDUREON and BYDUREON PEN (exenatide extended-release)
  8. Drugs@FDA: NDA 209210, BYDUREON BCISE (exenatide extended-release)
  9. Drugs@FDA: ANDA 206697, exenatide (Amneal)
  10. Holman RR et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL). N Engl J Med. 2017 (PubMed 28910237)
  11. Vijiaratnam N et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease (Exenatide-PD3). Lancet. 2025 (PubMed 39919773)
  12. FDA Orange Book data files, products.txt (data dated October 9, 2026)

More in More GLP-1 drugs